Survival curves were plotted in www.kmplot.com for all GC patients (n = 876), gastric intestinal type adenocarcinoma (n = 320), diffuse gastric adenocarcinoma (n = 241), HER2-negative GC (n = 532), and HER2-positive GC (n = 344). This evidence concerns the gene ERBB2 and diffuse gastric adenocarcinoma.